News ArchivesRead News
Gene Therapy Tried for Parkinson’s
Thursday December 22, 2005
December 19, 2005(The Louisiana Weekly) - Mike Castle lay motionless as surgeons drilled two holes into his skull and injected a virus deep into his brain. The virus carries a gene and a tantalizing hope: that just maybe it could stall the Parkinsons disease slowly crippling him.
The Illinois man is among a few dozen patients enrolling in the first attempts at gene therapy for Parkinsons, a milestone in the quest to better treat the degenerative brain disease.
Its a time of mixed excitement and caution: These first three studies are to see if gene therapy is safe to try, not to prove whether it works. Yet studies in monkeys suggest at least one of the approaches has the potential to finally target the underlying disease, not merely tame its symptoms.
"Its this delicate balance between giving (patients) hope but making it clear to them, and to the world, that this is still highly experimental," says Dr. William J. Marks Jr. of the University of California, San Francisco, who is leading the most closely watched approach - using a nerve growth factor to rescue dying brain cells.
"Its a gamble," agrees Dr. Leo Verhagen of Chicagos Rush University Medical Center, a co-researcher in the project who treated Castle.
"This is the first trial that, if it works, could slow down the diseases progression," he explains.
Yet to stress the experiments unknowns, he bluntly told Castle, "We are happy if we dont make you worse."
Parkinsons disease gradually destroys brain cells that produce dopamine, a chemical crucial for the cellular communication that controls muscle movement. As dopamine levels drop, symptoms increase: tremors in the arms, legs and face; periodically stiff or frozen limbs; slow movement; impaired balance and coordination. It afflicts about 1.5 million Americans.
Standard treatments are to replace lost dopamine with the drug levodopa, and a brain implant to control tremors. Both work for a while, but cant stop the diseases inevitable march.
To do that, scientists have long sought ways to protect remaining dopamine-producing neurons, or nerve cells, and rescue dying ones. A candidate: growth factors, protective proteins naturally found in healthy brains.
In the UCSF and Rush study, the brains of 12 patients are being injected with a harmless virus that carries the gene for one growth factor, called neurturin.
Neurturin is a sister to the better-known growth factor GDNF, an experimental drug believed to be showing promise against Parkinsons until a study infusing it directly into the brain was halted for safety concerns. Moreover, infusions dont allow the growth factor to spread deep enough to reach Parkinsons most crucial brain region, Verhagen says.
Scientists hope gene therapy can get around those issues. Rush neuroscientist Jeffrey Kordower found that monkeys with Parkinsons-like damage significantly improved within three months of receiving growth-factor gene therapy, as injured neurons were rescued. He co-founded California-based Ceregene Inc., which is developing the neurturin gene therapy.
"Gene therapy offers another mechanism in which to get these growth factors into the brain," said Diane Murphy, a neurodegenerative disease specialist at the National Institutes of Health. "Thats why people are interested in this, since the infusion methods seem to be problematic."
Two additional gene-therapy approaches:
Other UCSF researchers are hoping to lengthen the time patients can benefit from Parkinsons medication, through gene therapy designed to spur production of an enzyme that converts levodopa into dopamine. Three patients so far have received a gene-bearing virus, with 12 more to be enrolled.
And Neurologix Inc. recently announced promising preliminary results from 12 patients who tested an attempt to calm overactive brain activity involved with abnormal movements by boosting production of another neurochemical. The gene therapy seemed safe and, a year later, patients showed some improvement, the company said.
Aside from infection and bleeding as side effects of the brain injections, gene therapys biggest risk is that it cant be switched off if side effects appear.
But, "patients are more willing to take risks with something that may help in a more fundamental way," notes NIHs Murphy.
Thats why Castle, 46, enrolled. Medication controlled his symptoms for over a decade, but he finds it increasingly difficult to walk, with episodes of stumbling and freezing. About two months after undergoing gene therapy, Castle says he notices small improvements in walking, episodes his doctors greet cautiously.
"As far as I was concerned, it was the opportunity of a lifetime," Castle says. "If it works, Im ecstatic. If it doesnt, Ill be disappointed, but Ill at least know I tried."
Recent NewsOct 18 - Fighting Parkinson's disease through dance
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations
Oct 17 - Scientists Identify Structure of PINK1, Key Parkinson’s-protective Protein
Oct 17 - Diabetes drug cuts Parkinson's risk by 28 percent, study finds
Oct 10 - Advances in Brain Pacemaker Reduces Tremors, Helps Parkinson's Sufferers Live a More Normal Life
Oct 10 - Medical History Could Help Predict Parkinson's Disease Risk Long Before Diagnosis
Oct 3 - Changes in Olfactory Bulb Explain Loss of Smell in Early Stages of Parkinson’s Disease, Study Finds
Oct 3 - Sleep Disturbances May Worsen Motor Symptoms in Parkinson’s Disease, Study Suggests
Sep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show